4332 related articles for article (PubMed ID: 28838390)
1. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
[TBL] [Abstract][Full Text] [Related]
7. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
Deng M; Ma X; Liang X; Zhu C; Wang M
Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
9. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
Shao N; Cai Q
Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
[TBL] [Abstract][Full Text] [Related]
10. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
[TBL] [Abstract][Full Text] [Related]
11. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Yılmaz U; Ozdemir O; Batum O; Ermin S
Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.
Zhang H; Xia H; Zhang L; Zhang B; Yue D; Wang C
Am J Surg; 2015 Sep; 210(3):526-35. PubMed ID: 26105800
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.
Cruz-Ramos M; Del Puerto-Nevado L; Zheng B; López-Bajo R; Cebrian A; Rodríguez-Remirez M; García-García L; Solanes-Casado S; García-Foncillas J
J Geriatr Oncol; 2019 Sep; 10(5):742-748. PubMed ID: 30327283
[TBL] [Abstract][Full Text] [Related]
15. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
Kiriu T; Yamamoto M; Nagano T; Hazama D; Sekiya R; Katsurada M; Tamura D; Tachihara M; Kobayashi K; Nishimura Y
PLoS One; 2018; 13(2):e0193018. PubMed ID: 29447258
[TBL] [Abstract][Full Text] [Related]
16. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
[TBL] [Abstract][Full Text] [Related]
17. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.
Liu D; Jin J; Zhang L; Li L; Song J; Li W
Cell Physiol Biochem; 2018; 46(4):1595-1605. PubMed ID: 29694985
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: a meta-analysis.
Yang HB; Xing M; Ma LN; Feng LX; Yu Z
Oncotarget; 2016 Nov; 7(47):76769-76778. PubMed ID: 27732958
[TBL] [Abstract][Full Text] [Related]
19. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
[TBL] [Abstract][Full Text] [Related]
20. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]